Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance

Merck & Co., Inc.

Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).
GAAP loss per share $0.54; non-GAAP loss per share $0.13; both include $2.31/share charge for Terns acquisition.
Full-year 2026 guidance: sales range raised to $66.3B-$67.3B; non-GAAP EPS $2.66-$2.76 (includes $2.43/share Terns charge).
FDA approved LIPFENDRA (enlicitide), first once-daily oral PCSK9 inhibitor for hypercholesterolemia.
Completed acquisition of Terns for $6.8B; added MK-4208 (BCR::ABL1 inhibitor) to pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.